New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center Medical experts highlight second-line options for treating patients with DLBCL.
EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
EP. 3: Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
EP. 4: Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
EP. 5: Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
EP. 6: Panel Discuses Use of CD19 Bispecifics in Sequencing By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
EP. 7: Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.
EP. 8: Current Approach to Bridging Therapy in R/R DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART
EP. 9: Risk of Secondary Malignancies in Heavily Pre-Treated Population By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.
EP. 10: Management of CRS and ICANS with CAR T-cell Therapy By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.
EP. 11: Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center EP. 12: Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center EP. 13: Bispecific therapy – treatment setting and management of short-term adverse events By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center EP. 14: Bispecific therapy – management of long-term adverse events in the community setting By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center EP. 15: Practice Patterns and Real Use of Epcoritamab and Glofitamab By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the role of odronextamab.
EP. 16: Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL By Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
